Sign up
Pharma Capital

Silence Therapeutics believes a number of drug developers may need to licence its technology following US patent grant

“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio,” said Silence chief executive Ali Mortazavi
DNA sequence
The company specialises in RNA interference, a cellular process of silencing unwanted or harmful genes

Silence Therapeutics PLC (LON:SLN) saw its shares rise today on news it has been granted a US patent, which it believes significantly strengthens its claim to ownership of technology used in competitors’ late stage drugs.

The award covers the innovative chemical modification technology pioneered by Silence.

In afternoon trading, Silence shares were up nearly 3% at 210p.

READ: Silence Therapeutics eyes late stage payments as it widens patent net for gene silencing tech

The AIM-listed biotech, which specialises in RNA interference (RNAi), a cellular process of silencing unwanted or harmful genes, believes it could have implications for competitor Alnylam Pharmaceuticals' Patisiran drug.

Key to new treatment?

A treatment for a rare condition called TTR-mediated Amyloidosis (which leads to a protein build up in the body), Patisiran performed positively in a phase III clinical trial.

“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio,” said Silence chief executive Ali Mortazavi.

READ: Drug developer Silence Therapeutics on transition, transformation and the exciting year ahead

“This includes Patisiran, which is currently the most advanced RNAi drug in clinical development and has recently shown positive top line phase III results.

“We are highly encouraged by this field-validating event and excited for the prospects of patients living with ATTR."

Analysts said they expect today’s announcement to further assure shareholders of Silence’s ongoing focus on protecting its patent estate and, if proven, lead to potential revenues through licences under the patent portfolio.

 -- Adds share price, analyst comment ..

Ian_55ae0ddd437b7.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.